The Centers for Disease Control and Prevention (CDC) provides extensive data that indicate our need for drugs to maintain human population health. Despite the substantial availability of drugs on the market, many patients lack specific drugs. New drugs are required to tackle this issue. Moreover, we need more reliable models for testing drug toxicity, as too many drug approval failures occur with the current models. This article briefly describes various approaches of the currently used models for toxicity screening, to justify the selection of in vitro cell-based models. Cell-based toxicity models have the best potential to reliably predict drug toxicity in humans, as they are developed using the cells of the target organism.
In the year 2016, the Center for Disease Control and Prevention (CDC) recorded 883.7 million physician office visits in the United States (US). Among all those physician office visits, 653.5 million visits involved drug therapy (i.e. 73 .9% of all the visits) [1] . Moreover, 80 .4% of hospital emergency department visits involved drug therapy in 2016 in the US [2] .These two figures illustrate the irrefutable need for drugs in human healthcare. Moreover, each patient needs a specific drug. Despite the substantial drug availability in the market there are many patients that lack their specific drug. Therefore, novel drugs are needed to tackle this issue. Although, many drugs are marketed safely, notorious failures occurred when using the existing drug approval process to predict drug's toxicity. On one hand, safe drugs were categorized as unsafe [3] , and on the other hand, drugs that are unsafe were place on the market (until 2017, 417 commercial drugs were withdrawn because they caused severe adverse reactions on patients, even death) [4] [5] [6] . Furthermore, the existing drug approval process is both time and money-consuming, which is also reflected in the longevity of bringing a new drug to the market (approximately 10 years) and its overall development costs that often exceed a billion dollars [7] .
The above-mentioned numbers indicate that the process is not efficient. One of the main reasons for this lack of efficiency may be our lack of knowledge. For instance, looking at the cell biology history, in 1838 a series of three beliefs were established as the cell theory, one of which was demonstrated to be false a hundred years later [8, 9] . Similarly to what happened with cell theory, the beliefs we hold now regarding the existing drug approval process might turn out to be incorrect. Therefore, the drug approval process shall improve its reliability when predicting drug toxicity.
There are several features on the drug approval process that might be changed to improve the process' reliability, but the authors will focus on the lack of cohesion between preclinical and 2 clinical research to increase the drug approval process' reliability. Despite the fact that we are unaware of all the connected mechanisms that regulate cell physiology, the majority of preclinical research is based on specific cellular pathways, while clinical research focuses on homeostasis monitoring [10, 11] . Therefore, the preclinical and clinical research endpoints are essentially too far apart for us to create a continuous monitoring throughout the drug approval process.
In the present work, the authors will briefly describe the various toxicological model categories' premises and will discuss the distinct differences amongst them. This overview will justify that in vitro toxicological cell-based models are the models with the highest potential to become a reliable model for the human organism in the long-term future. Due to this higher potential, the authors propose upgrades for the in vitro toxicological cell-based models. The proposed upgrades (thoughtfully described in the following chapters) are focused on narrowing differences between preclinical and clinical research, even though these upgrades may have a wider influence.
<H1>TOXICOLOGICAL MODELS
Toxicity may be defined as "the degree to which a substance (a toxin or poison) can harm humans or animals" [12] . There are several interpretations attributable to the definition's extended meaning, which is the base for the many different approaches to measuring toxicity [13] .
Toxicological models were created to measure the harm that a substance could infringe on the human organism. Nowadays, there are three broad categories to assess toxicity in preclinical research; in silico, in vivo, and in vitro, [14] and one category for clinical research (subdivided into three phases) [15] . The existing drug approval process manages these categories as needed [15] .
In this chapter, we will briefly describe the various toxicological model's premises, the distinct differences amongst them and the most notorious drug approval process failures when predicting drug's toxicity (as the distinct differences between models may contribute to the drug approval process failures). This overview will be the founding on which we will base our suggested upgrades for in vitro toxicological cell-based models.
<H2>The in silico model
In silico means: "performed on a computer or via computer simulation" [14] . This model is mainly used as a toxicity model to predict how drugs interact with the body. The short assay duration and the reduce research costs are the in silico model's main advantages [14] . There are several in silico models (and approaches) to measure toxicity, and accordingly many ways for their classification [16] .
Since the in silico approach is performed by computer simulation, to get an output from the model, an algorithm should be built to transform the given input [17] . But, as explained above, there are many uncertainties and unknown linked processes in the human organism [11] . Due to this lack of information, the algorithms on which in silico models based their calculations are not complete. As a result, there is usually not enough data for the computer simulation to get a representative output from the in silico model.
<H2>The in vivo model
In vivo tests refer to experimentation using a whole living organism. The advantages are physiological reactions and interactions consideration, and a large harmonized database [14] .
Animal testing for toxicity measurements is commonly still related to the belief that if properly assessed, the effect of any compound tested in a laboratory animal is also relevant to humans [13] . Among the many in vivo research endpoints, the most common outcome is the "No Observed Adverse Effect Level" (NOAEL), which has to be determined prior to launch of the clinical phase for investigational products [13] . 4 The in vivo model is the only model that considers whole organisms (physiological reactions and interactions), and subsequently, is the only model that provides information regarding drug distribution and possible interactions with non-targeted organs. Thus, in vivo research arguably delivers the most representative toxicological and physiological models.
Nevertheless, in vivo models are also not without limitations, especially considering the significant differences between the animal and human organisms [18] . These differences were observed from the molecular level to organ cellular composition, which subsequently, lead to differences in organ composition ( Figure 1 ) [19] [20] [21] . To point out an important functional difference example, normal mouse blood pH (7.3-7.4) partially overlaps with the pathophysiological human blood pH range (<7.35 and >7.45) [22, 23] . Moreover, small differences may lead to big changes in organisms, as occurs on single point mutations (SPM) or aseptic conditions [24, 25] .
Therefore, any failure on toxicity prediction with in vivo models is most likely to be due to previously described differences between animals and humans. Moreover, fewer improvements are possible on in vivo models as they are close to their toxicity assessment potential.
<H2>The in vitro model
In vitro tests subtract specific parts (e.g. organ, tissue, cell) of a given organism to study it in a controlled environment, by which the noise provided by the studied part's surroundings, either inside or outside of the organism, is reduced. The model advantages are time, costs, and representativeness (as the model's material is from the target organism) [14] . Among the many in vitro toxicological models, we will focus on the cell-based in vitro models. While in vitro cell-based models should consider these processes (even though we are unaware of all these processes), there is a high probability that any other in vitro model neglects elements or processes occurring within the cell [11] . 5 The recently designed in vitro toxicological models' complexity reach the multi-organ organizational level, and in certain situations, these models are more accurate than in vivo models [27] . But the majority of the existing models are not fit to represent the target organism because the research is often simplified to such an extent that they lose one or more vital characteristics.
Most organ-based models lack the target organ's various cell lines. Consequently, this model neglects that a substance with non-observable toxicity to a particular cell line(s) may be toxic to other cell lines contained in the target organ. One of the best examples is the human liver in vitro toxicological models because many pathological processes are originated in liver fibroblasts while most in vitro toxicological research is based on liver hepatocytes [28] . On the other side, a substance tested on a single cell line with observable toxicity may not be toxic to the organ because the organ may compensate the imbalance.
Although most of the human organism's processes are interconnected, in vitro models mainly focus on biomolecules involve on a particular cell pathway ( Figure 2 ). In vitro toxicological research related to specific cell impairments may not be relevant because neglects the cell self-repair ability (even at the DNA level) [29] . Moreover, the organ's various cell types contribution and synchronization (physiological rhythm) maintain organ homeostasis. The organ's answer to the same input dramatically changes if any physiological rhythm is modified or omitted [30] . Likewise, the same input may result in different outputs depending on the cell population size (as happens on organ-on-a-chip models, where cell population size is too small) ( Figure 2 ).
Most in vitro toxicological models define a moment at which the toxicological tests are ended rather than monitoring the toxicity. Thus, a substance may induce toxicity to a cell in a given moment which may be self-repaired, resulting in a nontoxic substance in a later moment. Furthermore, the organisms' homeostasis may be recovered even after an acutely high 6 (possibly toxic) exposure [29] . On the other side, a substance may not induce toxicity to a cell in a given moment but induce toxicity to the cell after a certain period.
<H2>Clinical model
The clinical model is the last step of the drug approval processes because it is indisputable that the model that best mimics the target organism is the target organism itself. Clinical research monitors the body's chemical balance and metabolism, and their main endpoint is the homeostatic imbalance. After meticulous clinical research, physicians observed that certain biomolecules were present in higher or lower concentrations when patients were ill. Thus, these biomolecules are organism's homeostasis benchmarks [10, 31] .
<H2>Comparison and evaluation of different toxicological model categories
The various toxicological model categories' approaches are significantly different from each other, and so are their endpoints. Consequently, it is challenging to gather information for a systematic comparison between models ( Figure 3 ) [31] [32] [33] [34] [35] [36] . Moreover, miscellaneous endpoints between toxicological model categories may as well be the reason for the observed paradoxical effects between models [31] [32] [33] , [35] , [36] and the many drug approval process' failures ( Table 1) .
<H1>PROPOSED ELEMENTS TO UPGRADE EXISTING IN VITRO

TOXICOLOGICAL MODELS
As discussed above, the drug approval process may not properly evaluate the drug's toxicity and, thus, the evaluation process needs to be improved. Enhancing the cohesion between toxicological models may improve the existing drug approval process' reliability. Amongst the various toxicological models, the in vitro model is the model with the highest potential to develop a reliable cohesion with the clinical model (as described above). Nevertheless, there are important issues and limitations related to the existing in vitro toxicological models that have to be upgraded to achieve the desired level of reliability. The following paragraphs provide an insight into the most important upgrades that need to be considered in future Cell death methods should focus on determining death cells rather than determining viable cells to improve their trustworthiness regarding the cell viability determination.
In vitro toxicological models' endpoint shall consider two parameters for toxicity assessment: The upgraded model will be tested on different drugs to evaluate the model's reliability.
The following subchapters describe the above-mentioned elements in more detail and discuss the upgraded model's limitations.
<H2>Homeostatic imbalance
We may determine a substance's toxicity to humans as the harm this substance inflicts on the human organism. Hence, analyzing the substance's capability to induce failures on the human organism's homeostatic machinery ( Figure 4 ) [47] .
A set of organs and organs systems establish the human organism. According to the "property of the union of sets" a set union is impaired if any set is impaired. Thus, the organism's homeostasis is properly functional only if the homeostatic range of all respective organs is kept [48] . Key biomolecules are produced and used within the organ to keep the organ on its specialized function and within the homeostatic range (usually, not many of these biomolecules reach the bloodstream) [49] . The biomolecules synthesis is a fragment of many synchronized physiological reactions that happen simultaneously or consecutively to maintain organism's homeostasis. Any alteration of this "harmony" may lead to significant changes in the organism's homeostasis. Concretely, genetic polymorphisms may influence an up to 10fold variation in the metabolic activity [50, 51] . Furthermore, individual's physiological processes differences occur due to illness or variations in metabolic demands.
The organism synthesizes many different biomolecules to regulate the above-mentioned physiological processes, which distorts the genuine underlying trends of particular physiological processes related to particular biomolecules (phenomenon collectively termed "noise"). Some biomolecules are already detected and related to physiological processes (biomarkers used in clinical research). On account of this "noise", many biomolecules are undetected and unrelated to pathological processes that lead to organism's homeostatic imbalances [54, 55] . A systematic and thought-through design of novel in vitro models, where it is up to the researcher how to manage the model's conditions, could enable a minimization of the "noise" within the model, reducing the study from the full organism's homeostasis to the homeostasis of each organ, respectively [49] . This "noise" reduction should enable the detection of particular biomolecules related to particular homeostatic processes. A particular biomolecule selection shall be based on the biomolecule's function relevance for the respective organ's homeostasis. In addition, a preference for biomolecules that are observed as potential "early" biomarkers should be set (as they may be more useful in clinics). In any case, in vitro toxicological model should contain all the cell types that constitute the represented organ (due to reasons described in "2.3 in vitro model").
The suggested upgrades should facilitate a more comprehensive understanding regarding the organ's contribution to his own homeostasis as well as to organ's homeostasis.
<H2>Cell density
Any given input (cell signal, chemical imbalance, …) undergo many different related processes within the cell resulting in different possible outputs (gene expression, cell movement, molecule transport…). Many cells (and many repetitions) are needed to identify the output with the highest probability due to the various output's probabilities (as seen in Figure 2 ) [56] .
Extracellular fluid, especially interstitial fluid (IF), interacts with the cells to maintain the organ's homeostasis [57] . Any IF alteration would subsequently disturb the interaction between IF and the cell. Concretely, it was observed that interstitial fluid accumulation result in a modification in protein composition and gene regulation [58, 59] . Under this premise, too much media may alter the cell's homeostatic mechanisms.
Blood represents about human organism's 7 wt.%, while cell culture medium commonly represents more than the in vitro model's 90 wt.%. Consequently, the biomolecules are very diluted in the cell culture media and they can't be measured with clinical instrumentation [60] .
Thus, cell culture models shall be designed with less cell culture medium to enable biomolecule measurement with clinical instrumentation and maintain the cell's homeostatic mechanisms. In addition, cell population should be adequate to observe the output with the highest probability from a given input.
<H2>Nutrient intake
Since the nutritional elements intake and excretion balances organ's homeostasis, any alteration in nutritional intake will accordingly change the homeostatic balance [10] .
Therefore, if cells are not being fed with similar nutrients as the target organism does, we may assume the in vitro models' homeostatic balance is not similar to the target organism's homeostatic balance [60] [61] [62] . The nutrient pathway through the various organs is neither considered (not all cells have the same enzyme machinery) [64, 65] . Based on the above assumptions:
i.
Human cells are unable to synthesize certain unsaturated fatty acids. Therefore, a saturated fatty acid rich medium forces cells to change their composition to a saturated fatty acid rich plasma membrane, which is larger, more saturated and more packed than unsaturated fatty acid rich plasma membranes. Consequently, larger, more saturated and more packed plasma membrane lowers cell fluidity resulting in a less favored drug transport to the cell cytoplasm [47] .
ii. Human cells may not be able to synthesize all the required sugars at the required rate, while in vitro models are solely provided with glucose. The lack of proper sugars will lead to a change in de novo synthesized proteins' glycosylation, which subsequently leads to a change in glycoprotein 's biological effect [47] .
iii. The availability of essential minerals and vitamins condition the several cell processes to keep homeostasis. Therefore, cells are often unable to perform these processes due to the lack of essential vitamins and minerals [66] .
Owing to these shortcomings, the cell composition in in vitro models may not be the same as the cell composition in the human organism, affecting also the analyzed properties of the models [67] . To minimize potential cell compositions change, the cell culture medium shall contain essential nutrients (different sugars, essential fatty acids, vitamins and minerals). The cell culture medium's nutrient concentration should be calculated based on the available clinical nutritional data (and recommended daily intake) for the target organ (considering the various cell type number in each model) [68] .
<H2>Cell shape
Since cell shape is closely related to its purpose, a change in cell shape will lead to a change in cell functioning [69, 70] . Cells need to change their shape to attached to cell culture plastic ware on in vitro models, which consequently leads to changes in their functions. The cell transport kinetics may be impaired since the distance between apical and basolateral distance is shortened when the cell shape is changed (among other consequences) [69, 70] .
An extracellular matrix that mimics the cells intrinsic environment may overcome the above mention issue [61, 63] . Furthermore, fibroblast should synthesize the specific ECM to the represented target organ model [71] .
<H2>Toxicokinetics
The existing in vitro toxicological models' limitations (technical limitations, the individual's genetic polymorphisms…) difficult target molecule in vitro toxicokinetic analysis [72, 73] .
Nevertheless, several approaches may improve the molecules in vitro toxicokinetic analysis.
Concretely, capillary type and the molecule size consideration may improve the potential molecules transport prediction through systemic circulation (Discontinuous Capillaries have a wider diameter than Continues Capillaries). Moreover, the molecules potential pathway should be determined since these molecules may be transported to different organs (which may be out of the study's scope) on different forms (bio-transformed or native form) [74] .
Considering the pathway and processes the molecule undergoes when entering the organism should improve the models' representativeness. For instance, designing the pathway probabilistic tree for the target molecule (similar to the in silico PBPK approach ) [16] . favor representativeness, which should increase increased through time (since every test will add cell populations and markers). However, a case by case study should be done to determine the point at which the homeostatic imbalance variable values are out of the homeostatic range because minor differences (not statistically significant) may lead to significant differences in 14 the biological effect (as explained in "2.2 in vivo model") [80] . In addition, cell's health should be monitored by other parameters common to each cell and known to be constant.
Since a similar population reduction in blood macrophage cells (possessing a high proliferation activity) or eye epithelial cells (possessing a low proliferation activity) has different consequences, we should also monitor the potential recovery of both variables after a homeostatic imbalance [81, 82] .
This approach should connect cell processes, enhance the cohesion and link the results through different studies because these studies would share the same target biomolecules.
<H2>Dose-response
Drug dosing is commonly defined as "mg drug/ cell culture medium volume (liters)" on in vitro toxicological models. On the other hand, drugs dose is most commonly set as "mg drug/kg body" in clinical practice [33, 36] . Due to diverging metrics observe above, translating the drugs dose-response results obtain on in vitro toxicological models to clinical research is troublesome.
The drug availability on in vitro toxicological models' cells and clinical model cells also vary.
Many drug molecules are available for each cell on in vitro models because cell culture medium to cell number ratio is very high. Higher drug molecule availability on in vitro models may result in a drug's biological effect underestimation on clinical models when translating the dose-response results. Likewise, the drug pharmacokinetic pathway also affects the drug molecule availability on target sites (for example, the drug molecule may be biotransformed when reaching target site) [13] .
Most in vitro research analyze the model 24 hours after dosing the test substance on a particular cell line, while drugs have commonly a one week intended period of use. This differences in drug exposure might lead to significantly different physiological and hence pharmacological results (drugs are metabolized at a certain rate, excreted…) [83] . If the several organ's health assessment biomolecules values would be similar on in vitro toxicological models, we shall expect that the in vitro model physiological processes share physiological processes with the organs on in vivo situation. In addition, in vitro models allow the insightful organ functioning research, which shall contribute to a more comprehensive organ physiological process understanding and a broader drug's biological effect understanding. Subsequently, the acquire understanding shall facilitate a more efficient (with lesser side effects) forthcoming drugs designing. The forthcoming drugs shall also cover 16 several pathologies, which nowadays remain uncovered [84] . Ideally, this approach shall also reduce both drug approval process duration and costs.
<H2>Limitations
The proposed upgrades have several advantages to the existing models, as they enable more sensible research data comparison between preclinical and clinical models. But several limitations and obstacles are still to be considered and addressed accordingly to build toxicological in vitro models that would fit human requirements (regarding toxicity prediction models).
The described upgrades do not offer solutions regarding possible genetic polymorphisms that are known to be very significant when analyzing the drug's biological effect.
Another model's limitation is related to physiological rhythm disregard (mainly due to limitations in our knowledge). In vitro toxicological model with interconnected target organ's subsets should be the model with the highest probabilities to be a representative model for the human organism.
Due to its complexity, the nurture is the biggest challenge (and limitation) to all models that aim to represent the human organism. And is neither consider in the upgraded model.
<H1>FUTURE PERSPECTIVES AND CONCLUSIONS
Despite the substantial drug availability in the market there are many patients that lack a specific drug. Although, many newly synthesize drugs are marketed safely, many failures and paradoxes were observed when assessing substances' toxicity with the existing drug approval process. Thus, is reasonable to suspect that existing toxicological models may considerably 
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